Understanding AWAT2: A Potential Drug Target for Diseases (G158835)

Target Name: AWAT2

NCBI ID: G158835

AWAT2

Understanding AWAT2: A Potential Drug Target for Diseases

AWAT2 (diacylglycerol O-acyltransferase candidate 4) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a key enzyme in the fatty acid biosynthesis pathway, which is responsible for the production of the fatty acids that make up the building blocks of life, including cholesterol, fatty acids, and ketones. The activity of AWAT2 has been implicated in the development and progression of a number of diseases, including cardiovascular disease, obesity, and neurodegenerative disorders. As As a result, AWAT2 has emerged as a promising drug target and biomarker for a variety of therapeutic approaches.

The fatty acid biosynthesis pathway is a complex series of reactions that involve the transfer of acyl groups from the amino acids to the carbonyl group of a lipid molecule. This process is critical for the production of the fatty acids that make up the cell membrane and are Involved in a wide range of physiological processes, including energy storage and transport. The AWAT2 enzyme is a key player in this pathway, as it catalyzes the transfer of acyl groups from the amino acids to the carbonyl group of the lipid molecule.

In addition to its role in fatty acid biosynthesis, AWAT2 has also been shown to play a number of other roles in various cellular processes. For example, it has been shown to be involved in the production of various signaling molecules, including neurotransmitters and hormones. It has also been shown to be involved in the regulation of cellular processes such as cell adhesion, migration, and apoptosis.

The development and progression of many diseases, including cardiovascular disease and neurodegenerative disorders, are influenced by changes in the levels of certain fatty acids in the body. For example, individuals with certain genetic mutations, such as those in the APC gene, are at increased risk for developing cardiovascular disease due to changes in the levels of omega-3 fatty acids in their bodies. Similarly, the production of certain fatty acids, such as saturated fatty acids, has been implicated in the development of neurodegenerative disorders such as Alzheimer's disease.

In conclusion, AWAT2 is a protein that plays a critical role in the fatty acid biosynthesis pathway and has been implicated in the development and progression of a number of diseases. As a result, it has emerged as a promising drug target and biomarker for a variety of therapeutic approaches. Further research is needed to fully understand the role of AWAT2 in various cellular processes and to develop effective treatments for the diseases associated with its dysfunction.

Protein Name: Acyl-CoA Wax Alcohol Acyltransferase 2

Functions: Acyltransferase that catalyzes the formation of ester bonds between fatty alcohols and fatty acyl-CoAs to form wax monoesters (PubMed:15220349, PubMed:15671038, PubMed:16106050, PubMed:28420705). Shows a preference for medium chain acyl-CoAs from C12 to C16 in length and fatty alcohols shorter than C20, as the acyl donors and acceptors, respectively (PubMed:15220349, PubMed:15671038). Also possesses acyl-CoA retinol acyltransferase (ARAT) activity that catalyzes 11-cis-specific retinyl ester synthesis (PubMed:16106050, PubMed:24799687). Shows higher catalytic efficiency toward 11-cis-retinol versus 9-cis-retinol, 13-cis-retinol, and all-trans-retinol substrates (PubMed:24799687)

The "AWAT2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AWAT2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets